Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom to Raise $51.6M in Private Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom today said that it has entered into an agreement to sell $51.6 million worth of its common stock to unnamed investors in a private placement.

The San Diego-based molecular diagnostics firm said that it will sell 12,435,000 shares of its common stock at a price of $4.15 per share to certain investors. It expects to close the financing on or around May 17.

Sequenom intends to use the funds to continue its R&D efforts and for commercialization of diagnostic tests, as well as for general corporate purposes.

Last week, Sequenom reported its first-quarter financial results and detailed its plans for developing and commercializing its non-invasive Down syndrome test.

It hopes to launch a laboratory-developed test on the market by the end of 2011. It also plans to complete the appropriate studies and documentation necessary to file for premarket approval of the T21 test by the end of 2012.

As of March 31, Sequenom held $29.2 million in cash, and short- and long-term marketable securities.

In early Wednesday trade on the Nasdaq, shares of Sequenom were down nearly 4 percent at $5.18.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.